ArticleEJHaem2020
A pilot clinical phase II trial MemSID: Acute and durable changes of red blood cells of sickle cell disease patients on memantine treatment.
Article in EJHaem, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- MeMAGEN: A Phase IIa/IIb open-label trial of memantine testing safety and tolerability in sickle cell patients.HemaSphere · 2026Article
- From old to new: Repurposed drugs in the battle towards curing sickle cell disease.British journal of haematology · 2025Article
- Sickle cell disease: combination new therapies vs. CRISPR-Cas9 potential and challenges - review article.Annals of hematology · 2024Review
- Molecular and environmental contributors to neurological complications in sickle cell disease.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Methemoglobinemia, Increased Deformability and Reduced Membrane Stability of Red Blood Cells in a Cat with aCells · 2023Article
- Deregulated calcium signaling in blood cancer: Underlying mechanisms and therapeutic potential.Frontiers in oncology · 2022Review
- Article
- The Transient Receptor Potential Vanilloid Type 2 (TRPV2) Channel-A New Druggable CaFrontiers in physiology · 2021Article
- MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease.HemaSphere · 2020Article
- Article
- Trends in the Development of Diagnostic Tools for Red Blood Cell-Related Diseases and Anemias.Frontiers in physiology · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increase in abundance and activity of N-methyl D-aspartate receptors (NMDAR) was previously reported for red blood cells (RBCs) of sickle cell disease (SCD) patients. Increased Ca
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.